Edwards Historical Cash Flow
EW Stock | USD 88.63 0.88 1.00% |
Analysis of Edwards Lifesciences cash flow over time is an excellent tool to project Edwards Lifesciences Corp future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Depreciation of 81.8 M or Other Non Cash Items of 10 M as it is a great indicator of Edwards Lifesciences ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Edwards Lifesciences Corp latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Edwards Lifesciences Corp is a good buy for the upcoming year.
Edwards |
About Edwards Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Edwards balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Edwards's non-liquid assets can be easily converted into cash.
Edwards Lifesciences Cash Flow Chart
Edwards Cash Flow Statement became part of mandatory reporting in 1987. It is now one of three main statements in accounting used to measure how well a company manages its liquidity and overall cash position. The rate of cash utilization and preservation is now part of the leading indicators of a healthy entity, and the Edwards Lifesciences Corp Cash Flow Statement shows how well the company generates cash to payout debt obligations or to cover ongoing operating expenses.
At this time, Edwards Lifesciences' Net Income is fairly stable compared to the past year. Change In Cash is likely to climb to about 394.2 M in 2024, whereas Free Cash Flow is likely to drop slightly above 444.3 M in 2024. Add Fundamental
Free Cash Flow
The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.Capital Expenditures
Capital Expenditures are funds used by Edwards Lifesciences Corp to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Edwards Lifesciences operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in Edwards Lifesciences Corp financial statement analysis. It represents the amount of money remaining after all of Edwards Lifesciences Corp operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Most accounts from Edwards Lifesciences' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Edwards Lifesciences Corp current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Edwards Lifesciences Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in housing. At this time, Edwards Lifesciences' Net Income is fairly stable compared to the past year. Change In Cash is likely to climb to about 394.2 M in 2024, whereas Free Cash Flow is likely to drop slightly above 444.3 M in 2024.
Edwards Lifesciences cash flow statement Correlations
Click cells to compare fundamentals
Edwards Lifesciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Edwards Lifesciences cash flow statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Change To Inventory | (105.4M) | (120.6M) | 19M | (213.4M) | (289M) | (274.6M) | |
Free Cash Flow | 901M | 647M | 1.4B | 953.4M | 629.5M | 444.3M | |
Change In Working Capital | (204.3M) | 42.2M | 145.3M | (421.4M) | (526.3M) | (500.0M) | |
Other Cashflows From Financing Activities | 35M | 155.5M | 163.5M | 142.8M | 168.9M | 160.5M | |
Depreciation | 89.3M | 107.2M | 134.8M | 139.6M | 144.9M | 81.8M | |
Other Non Cash Items | 154.1M | 38.3M | (119M) | 105.8M | 10.5M | 10.0M | |
Capital Expenditures | 278.4M | 407.3M | 329.8M | 264.8M | 266.3M | 146.6M | |
Total Cash From Operating Activities | 1.2B | 1.1B | 1.7B | 1.2B | 895.8M | 590.9M | |
Net Income | 1.0B | 823.4M | 1.5B | 1.5B | 1.4B | 1.5B | |
Total Cash From Financing Activities | (115.6M) | (486.9M) | (356.3M) | (1.6B) | (711M) | (675.5M) | |
Change In Cash | 465M | 15.8M | (332.8M) | (94.8M) | 375.4M | 394.2M | |
End Period Cash Flow | 1.2B | 1.2B | 867.4M | 772.6M | 1.1B | 1.2B | |
Other Cashflows From Investing Activities | (183.2M) | (22.4M) | (61.5M) | 517.1M | 465.4M | 488.7M | |
Stock Based Compensation | 81.3M | 92.6M | 109.3M | 126.8M | 139.4M | 146.4M | |
Begin Period Cash Flow | 714.1M | 1.2B | 1.2B | 867.4M | 772.6M | 499.0M | |
Change To Liabilities | (20.3M) | (137.4M) | 257.2M | (27M) | (31.1M) | (29.5M) | |
Sale Purchase Of Stock | (263.3M) | (625.4M) | (512.8M) | (1.7B) | (879.6M) | (835.6M) | |
Change To Account Receivables | (94.8M) | 283.9M | (112.4M) | (84.1M) | (141.2M) | (134.1M) | |
Total Cashflows From Investing Activities | (595.8M) | (531.1M) | (1.7B) | 252.3M | 227.1M | 238.4M | |
Dividends Paid | 18.9M | 140.5M | 158.6M | 146.4M | 169.9M | 233.1M | |
Investments | (158.2M) | (101.7M) | (1.3B) | 252.3M | 254.4M | 267.1M | |
Change Receivables | (88M) | 41.9M | (91.1M) | (84.1M) | (75.7M) | (71.9M) | |
Net Borrowings | (10M) | (800K) | (1.8M) | (200K) | (180K) | (171K) | |
Cash And Cash Equivalents Changes | 468M | 36.3M | (346.7M) | (114M) | (102.6M) | (97.5M) | |
Cash Flows Other Operating | 1.1B | 1.1B | 1.5B | 1.5B | 1.7B | 1.8B | |
Change To Netincome | 198.2M | 53.3M | (79.6M) | (49.1M) | (56.5M) | (53.6M) | |
Change To Operating Activities | 9.4M | 258.3M | (39.8M) | (96.9M) | (87.2M) | (82.8M) |
Pair Trading with Edwards Lifesciences
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Edwards Lifesciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Edwards Lifesciences will appreciate offsetting losses from the drop in the long position's value.Moving together with Edwards Stock
0.66 | HQY | HealthEquity Financial Report 3rd of June 2024 | PairCorr |
Moving against Edwards Stock
0.8 | SINT | SINTX Technologies | PairCorr |
0.68 | RSLS | ReShape Lifesciences | PairCorr |
0.63 | BBLG | Bone Biologics Corp Financial Report 20th of May 2024 | PairCorr |
0.63 | CMAX | CareMax Financial Report 8th of May 2024 | PairCorr |
0.56 | HCAT | Health Catalyst Financial Report 14th of May 2024 | PairCorr |
The ability to find closely correlated positions to Edwards Lifesciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Edwards Lifesciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Edwards Lifesciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Edwards Lifesciences Corp to buy it.
The correlation of Edwards Lifesciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Edwards Lifesciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Edwards Lifesciences Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Edwards Lifesciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Edwards Lifesciences Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in housing. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Complementary Tools for Edwards Stock analysis
When running Edwards Lifesciences' price analysis, check to measure Edwards Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edwards Lifesciences is operating at the current time. Most of Edwards Lifesciences' value examination focuses on studying past and present price action to predict the probability of Edwards Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edwards Lifesciences' price. Additionally, you may evaluate how the addition of Edwards Lifesciences to your portfolios can decrease your overall portfolio volatility.
Commodity Directory Find actively traded commodities issued by global exchanges | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Transaction History View history of all your transactions and understand their impact on performance | |
CEOs Directory Screen CEOs from public companies around the world | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation |
Is Edwards Lifesciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Edwards Lifesciences. If investors know Edwards will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Edwards Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.06) | Earnings Share 2.3 | Revenue Per Share 9.897 | Quarterly Revenue Growth 0.138 | Return On Assets 0.1225 |
The market value of Edwards Lifesciences Corp is measured differently than its book value, which is the value of Edwards that is recorded on the company's balance sheet. Investors also form their own opinion of Edwards Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Edwards Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Edwards Lifesciences' market value can be influenced by many factors that don't directly affect Edwards Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Edwards Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Edwards Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Edwards Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.